Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 04, 2020 | May 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date May 04, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,860 |
Ending reported balance
After 2020-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-04 · Exercise / conversion · Acquired 2,416 · Balance 57,276 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 2 · 2020-05-04 · Sale · Disposed 2,416 · Balance 54,860 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.63 · Expires 2020-05-11 | Direct | 0 |
Reported balance
After 2020-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-04 · Exercise / conversion · Disposed 2,416 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2015 Filed Oct 27, 2015 19:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-15-014232 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| October 26, 2015 Filed Oct 27, 2015 19:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,000 | $110.00 | $1,650,000.00 |
DisclosureSEC source: 0001179110-15-014232 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,309 Read SEC document |
| October 26, 2015 Filed Oct 27, 2015 19:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $20.71 | $310,575.00 |
DisclosureSEC source: 0001179110-15-014232 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2015 Filed Sep 17, 2015 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001104659-15-065753 · a4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 15,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| September 15, 2015 Filed Sep 17, 2015 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,000 | $110.00 | $1,650,000.00 |
DisclosureSEC source: 0001104659-15-065753 · a4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,309 Read SEC document |
| September 15, 2015 Filed Sep 17, 2015 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $20.71 | $310,575.00 |
DisclosureSEC source: 0001104659-15-065753 · a4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2015 Filed Aug 4, 2015 21:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-15-011692 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 15,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| August 03, 2015 Filed Aug 4, 2015 21:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,000 | $120.00 | $1,800,000.00 |
DisclosureSEC source: 0001179110-15-011692 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,309 Read SEC document |
| August 03, 2015 Filed Aug 4, 2015 21:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $20.71 | $310,575.00 |
DisclosureSEC source: 0001179110-15-011692 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2015 Filed Jun 30, 2015 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-15-010549 · edgar.xml · derivative · entry 5 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 15,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| June 26, 2015 Filed Jun 30, 2015 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-15-010549 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2016-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| June 26, 2015 Filed Jun 30, 2015 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 27,000 | $120.13 | $3,243,420.90 |
DisclosureSEC source: 0001179110-15-010549 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,309 F3 · price: Sale prices reported for the transactions reported here range from $120.00 to $120.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 26, 2015 Filed Jun 30, 2015 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $20.71 | $310,575.00 |
DisclosureSEC source: 0001179110-15-010549 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2015 Filed Jun 30, 2015 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 12,000 | $14.34 | $172,080.00 |
DisclosureSEC source: 0001179110-15-010549 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2015 Filed May 7, 2015 21:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 5,167 | $0.00 Strike: $102.27 | $0.00 |
DisclosureSEC source: 0001179110-15-007268 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,167 Underlying: Common Stock · 5,167 shares Expires 2025-05-06 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2015 Filed May 7, 2015 21:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007268 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466 Underlying: Common Stock · 1,466 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 05, 2015 Filed May 7, 2015 21:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007268 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 5, 2015. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 5, 2015. Read SEC document |
| May 05, 2015 Filed May 7, 2015 21:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007268 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 22, 2014 Filed Dec 24, 2014 17:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-018715 · edgar.xml · derivative · entry 8 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| December 22, 2014 Filed Dec 24, 2014 17:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 317 | $97.91 | $31,038.61 |
DisclosureSEC source: 0001179110-14-018715 · edgar.xml · nonDerivative · entry 7 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,405 F8 · price: Sale prices reported for the transactions reported here range from $97.91 to $97.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 22, 2014 Filed Dec 24, 2014 17:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,240 | $97.09 | $314,579.05 |
DisclosureSEC source: 0001179110-14-018715 · edgar.xml · nonDerivative · entry 6 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,722 F7 · price: Sale prices reported for the transactions reported here range from $96.69 to $97.68. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 22, 2014 Filed Dec 24, 2014 17:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,400 | $96.28 | $616,181.76 |
DisclosureSEC source: 0001179110-14-018715 · edgar.xml · nonDerivative · entry 5 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,962 F6 · price: Sale prices reported for the transactions reported here range from $95.69 to $96.68. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 22, 2014 Filed Dec 24, 2014 17:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,071 | $94.97 | $481,574.11 |
DisclosureSEC source: 0001179110-14-018715 · edgar.xml · nonDerivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,362 F5 · price: Sale prices reported for the transactions reported here range from $94.66 to $95.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 22, 2014 Filed Dec 24, 2014 17:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,322 | $94.13 | $500,935.91 |
DisclosureSEC source: 0001179110-14-018715 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,433 F4 · price: Sale prices reported for the transactions reported here range from $93.65 to $94.61. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 22, 2014 Filed Dec 24, 2014 17:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,650 | $93.18 | $526,445.53 |
DisclosureSEC source: 0001179110-14-018715 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,755 F3 · price: Sale prices reported for the transactions reported here range from $92.60 to $93.59. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 22, 2014 Filed Dec 24, 2014 17:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 26,000 | $14.34 | $372,775.00 |
DisclosureSEC source: 0001179110-14-018715 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2014 Filed Nov 25, 2014 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-017079 · edgar.xml · derivative · entry 5 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 25,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| November 21, 2014 Filed Nov 25, 2014 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $102.51 | $256,275.00 |
DisclosureSEC source: 0001179110-14-017079 · edgar.xml · nonDerivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,405 Read SEC document |
| November 21, 2014 Filed Nov 25, 2014 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,515 | $101.55 | $763,172.30 |
DisclosureSEC source: 0001179110-14-017079 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,905 F4 · price: Sale prices reported for the transactions reported here range from $101.29 to $102.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 21, 2014 Filed Nov 25, 2014 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 14,985 | $100.86 | $1,511,322.66 |
DisclosureSEC source: 0001179110-14-017079 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,420 F3 · price: Sale prices reported for the transactions reported here range from $100.265 to $101.26. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 21, 2014 Filed Nov 25, 2014 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 25,000 | $14.34 | $358,437.50 |
DisclosureSEC source: 0001179110-14-017079 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2014 Filed Oct 23, 2014 17:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-015693 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 15,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| October 21, 2014 Filed Oct 23, 2014 17:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,098 | $104.67 | $114,925.57 |
DisclosureSEC source: 0001179110-14-015693 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,405 F4 · price: Sale prices reported for the transactions reported here range from $104.53 to $104.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 21, 2014 Filed Oct 23, 2014 17:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 13,902 | $104.03 | $1,446,223.67 |
DisclosureSEC source: 0001179110-14-015693 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,503 F3 · price: Sale prices reported for the transactions reported here range from $103.51 to $104.39. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 21, 2014 Filed Oct 23, 2014 17:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $14.34 | $215,062.50 |
DisclosureSEC source: 0001179110-14-015693 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2014 Filed Sep 24, 2014 17:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-014454 · edgar.xml · derivative · entry 5 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 5,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| September 22, 2014 Filed Sep 24, 2014 17:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,801 | $107.48 | $193,570.58 |
DisclosureSEC source: 0001179110-14-014454 · edgar.xml · nonDerivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,405 F5 · price: Sale prices reported for the transactions reported here range from $107.31 to $107.54. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 22, 2014 Filed Sep 24, 2014 17:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,303 | $106.60 | $138,894.20 |
DisclosureSEC source: 0001179110-14-014454 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,206 F4 · price: Sale prices reported for the transactions reported here range from $106.31 to $107.25. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 22, 2014 Filed Sep 24, 2014 17:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,896 | $105.76 | $200,522.10 |
DisclosureSEC source: 0001179110-14-014454 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,509 F3 · price: Sale prices reported for the transactions reported here range from $105.31 to $106.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 22, 2014 Filed Sep 24, 2014 17:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $14.34 | $71,687.50 |
DisclosureSEC source: 0001179110-14-014454 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2014 Filed Aug 25, 2014 16:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-013206 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 5,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| August 21, 2014 Filed Aug 25, 2014 16:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $101.09 | $505,439.50 |
DisclosureSEC source: 0001179110-14-013206 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,405 F3 · price: Sale prices reported for the transactions reported here range from $101.00 to $101.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 21, 2014 Filed Aug 25, 2014 16:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $14.34 | $71,687.50 |
DisclosureSEC source: 0001179110-14-013206 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2014 Filed Jul 23, 2014 17:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-011924 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 5,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| July 21, 2014 Filed Jul 23, 2014 17:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,196 | $90.16 | $107,827.29 |
DisclosureSEC source: 0001179110-14-011924 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,405 F4 · price: Sale prices reported for the transactions reported here range from $90.00 to $90.60. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 21, 2014 Filed Jul 23, 2014 17:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,804 | $89.52 | $340,515.44 |
DisclosureSEC source: 0001179110-14-011924 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,601 F3 · price: Sale prices reported for the transactions reported here range from $89.00 to $89.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 21, 2014 Filed Jul 23, 2014 17:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $14.34 | $71,687.50 |
DisclosureSEC source: 0001179110-14-011924 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2014 Filed Jun 25, 2014 17:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-010882 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 5,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| June 23, 2014 Filed Jun 25, 2014 17:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $81.82 | $409,122.50 |
DisclosureSEC source: 0001179110-14-010882 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,405 F3 · price: Sale prices reported for the transactions reported here range from $81.27 to $82.19. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 23, 2014 Filed Jun 25, 2014 17:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $14.34 | $71,687.50 |
DisclosureSEC source: 0001179110-14-010882 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.